Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTJGY7A)

• DTT Name: Complement C3 (CO3) DTT Info
• UniProt ID: CO3_HUMAN
• Gene Name: C3

Molecule-Related Drug & Molecule List

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
APL-2	DM4HQ52	Paroxysmal nocturnal haemoglobinuria	3A21.0	Phase 3	[1]
Imprime PGG	DMIUA3M	Non-hodgkin lymphoma	2B33.5	Phase 2/3	[2]
AMY-101	DMS0GA6	Gingivitis	DA0B	Phase 2	[3]
POT-4	DMH0LM2	Macular degeneration	9B78.3	Phase 2	[4]

28 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ac-ICV(1MeW)QDWGAHRCT-NH2	DM351NL	Discovery agent	N.A.	Investigative	[5]
Ac-ICV(5fW)QDWGAHRCT-NH2	DMQLPGA	Discovery agent	N.A.	Investigative	[5]
Ac-ICV(5MeW)QDWGAHRCT-NH2	DM52T90	Discovery agent	N.A.	Investigative	[5]
Ac-ICVWQD(5fW)GAHRCT-NH2	DMPK9LG	Discovery agent	N.A.	Investigative	[5]
Ac-ICVWQDWGAHRCT-NH2	DMPSI26	Discovery agent	N.A.	Investigative	[5]
Ac-I[CV(1Nal)QDWGAHRC]T	DMJVRPD	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(2Igl)QDWGAHRC]T	DM14DEL	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(2Igl)QDWGAHRC]T-NH2	DMQISG6	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(2Nal)QDWGAHRC]T	DM20PEO	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(2Nal)QDWGAHRC]T-NH2	DMX2IRY	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(Bpa)QDWGAHRC]T	DMDFKU3	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(Bpa)QDWGAHRC]T-NH2	DMZG46O	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(Bta)QDWGAHRC]T	DM5NMVP	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(Bta)QDWGAHRC]T-NH2	DMFLA5T	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(Dht)QDWGAHRC]T	DMO9VWH	Discovery agent	N.A.	Investigative	[6]
Ac-I[CV(Yphs)QDWGAHRC]I-NH2	DMY18ET	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVFQDWGHHRC]T-NH2	DMFOTYQ	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVHQDWGHHRC]T-NH2	DMLU3PZ	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVSQDWGHHRC]T-NH2	DMDPSBQ	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVTQDWGHHRC]T-NH2	DMNVMB5	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVVQDWGAHRC]T-NH2	DMRSKIY	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVWQDWG(Abu)HRC]T-NH2	DMUW3T4	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVWQDWGAHRC]dT	DML5ZSJ	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVWQDWGAHRC]T	DMV3PC7	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVWQDWGHHRC]T-NH2	DMBA1LS	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVWQDWGWHRC]T-NH2	DMDIUK6	Discovery agent	N.A.	Investigative	[6]
Ac-I[CVYQDWGAHRC]T-NH2	DM3Q5SU	Discovery agent	N.A.	Investigative	[6]
Cysteine Sulfenic Acid	DM4GZUJ	N. A.	N. A.	Investigative	[7]

References

• [1] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [2] National Cancer Institute Drug Dictionary (drug id 599816).
• [3] The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
• [4] Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292.
• [5] Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.
• [6] Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
• [7] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.